0001415889-24-010228.txt : 20240403
0001415889-24-010228.hdr.sgml : 20240403
20240403213012
ACCESSION NUMBER: 0001415889-24-010228
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240401
FILED AS OF DATE: 20240403
DATE AS OF CHANGE: 20240403
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lyssikatos Joseph P
CENTRAL INDEX KEY: 0001967150
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39247
FILM NUMBER: 24821392
MAIL ADDRESS:
STREET 1: 6200 LOOKOUT ROAD
CITY: BOULDER
STATE: CO
ZIP: 80301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Enliven Therapeutics, Inc.
CENTRAL INDEX KEY: 0001672619
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 811523849
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6200 LOOKOUT ROAD
CITY: BOULDER
STATE: CO
ZIP: 80301
BUSINESS PHONE: 720-647-8519
MAIL ADDRESS:
STREET 1: 6200 LOOKOUT ROAD
CITY: BOULDER
STATE: CO
ZIP: 80301
FORMER COMPANY:
FORMER CONFORMED NAME: IMARA Inc.
DATE OF NAME CHANGE: 20160419
4
1
form4-04042024_010402.xml
X0508
4
2024-04-01
0001672619
Enliven Therapeutics, Inc.
ELVN
0001967150
Lyssikatos Joseph P
C/O ENLIVEN THERAPEUTICS, INC.
6200 LOOKOUT ROAD
BOULDER
CO
80301
true
true
false
false
CHIEF SCIENTIFIC OFFICER
1
Common Stock
2024-04-01
4
M
0
12000
1.12
A
12000
D
Common Stock
2024-04-01
4
S
0
2352
17.7242
D
9648
D
Common Stock
2024-04-01
4
S
0
9577
18.8038
D
71
D
Common Stock
2024-04-01
4
S
0
71
19.3578
D
0
D
Common Stock
1117035
I
See footnote
Stock Option (right to buy)
1.12
2024-04-01
4
M
0
12000
0
D
2030-06-16
Common Stock
12000
260550
D
The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.
This transaction was executed in multiple trades at prices ranging from $17.335 to $18.255. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $18.35 to $19.325. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
This transaction was executed in multiple trades at prices ranging from $19.355 to $19.36. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.
The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020.
/s/ Ben Hohl, by power of attorney
2024-04-03